On October 14, 2026, Enliven Therapeutics increased its board size from seven to eight directors and appointed Kristine Ball as a Class II director with a term expiring at the 2028 annual meeting. Ms. Ball will serve on the Audit Committee and receive $55,000 in annual cash compensation plus stock options valued at approximately $650,000. The appointment supports the company's transition from clinical development to commercialization as it prepares to initiate a pivotal Phase 3 trial of relcobatinib before year-end. Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for unmet medical needs.
